Molecular docking based virtual screening of carbonic anhydrase IX with coumarin (a cinnamon compound) derived ligands

Krishnamoorthy Meenakumari¹, Giridharan Bupesh¹ ² *, Shakthivel Vasanth¹, C. Arul Vasu⁴, Kanniyan Pandian³, Kaliyperumal Prabhu⁶, S. Prasath @ Surendhar⁵

¹Research and Development Wing, Central Research Laboratory, Sree Balaji Medical College and Hospital (SBMCH), BIHER, Chrompet, Chennai - 600044, India; ²Department of Virology, King Institute of Preventive Medicine and Research, Guindy, Chennai - 600032, India; ³Department of Inorganic Chemistry, University of Madras, Guindy Campus, Tamil Nadu, India; ⁴Department of Zoology, University of Madras, Guindy Campus, Tamil Nadu, India; ⁵Department of Biomedical Engineering, Bharath Institute of Higher Education & Research, Chennai - 605005, Tamil Nadu, India; ⁶Department of Anatomy, Sree Balaji Medical College & Hospital, BIHER, Chrompet, Chennai; Corresponding Authors : Dr. Giridharan Bupesh, Associate Director, R&D Wing, Sree Balaji Medical College and Hospital, BIHER, Chrompet, TamilNadu-600044, Phone: +91 8012405965, Email: bupeshgiri55@gmail.com. *Corresponding author

Received September 27, 2019; Revised October 30, 2019; Accepted October 30, 2019; Published October 31, 2019

DOI: 10.6026/97320630015744

Abstract:
It is of interest to design carbonic anhydrase IX (CAIX) inhibitors with improved features using molecular docking based virtual high through put screening of ligands. Coumarin (a cinnamon compound with pharmacological activity) is known as a potent phytal compound blocking tumor growth. Hence, a series of 17 coumarin derivatives were designed using the CHEMSKETCH software for docking analysis with CAIX. The catalytic site analysis of CAIX for binding with ligand molecules was completed using the SCHRODINGER package (2009). Thus, 17 ligands with optimal binding features with CAIX were selected following the calculation of ADME/T properties. We report ligands #41, #42, #19 and #15 showed good docking score, glide energy and hydrogen bond interactions without vdW clash. We further show that N-(3,4,5-trimethoxy-phenylcarbamoylmethyl) designated as compound #41 have the highest binding energy (-61.58) with optimal interactions with the catalytic residues (THR 199, PRO 201, HIS 119, HIS 94) of CAIX.

Keywords: Carbonic anhydrase IX; coumarin; GLIDE; ADME/T; induced fit docking

Background:
Cancer is one of the biggest disease burden in both developing and developed countries. Ligand based virtual screening and lead identification for the design of new drugs for cancer treatment is gaining momentum [1]. It is known that cancer drugs are most commonly used by many patients in the world [2]. Recently, many attempts have been made to synthesize potential anticancer medications against several known targets. CAIX is a tumor-related isozyme which is up regulated in variety of hypoxic tumor cells [3, 6]. CAIX is associated with tumor development, metastasis, and gives an appropriate domain to hypoxic tumor cells survival and expansion [7, 8]. Thus, carbonic anhydrases (CAs) are zinc metallo enzymes known as a cancer target [3-5].

Carbonic anhydrase IX is the only known tumor-associated carbonic anhydrase isoenzyme. It is a member of the CA family since it is generally expressed in a limited number of normal
tissues, whereas its over expression is noted on the cell surface of a large number of solid tumors, and it is linked invariably with the hypoxic phenotype and it is mediated by the transcription factor HIF-1 [9]. Moreover, CAIX associates poor responsiveness to classical radiation and chemotherapy [10]. The expression of CAIX is highly up regulated by hypoxia, and down regulated by the wild-type von Hippe1-Lindau tumor suppressor protein (pVHL) [11, 12]. Since CAIX has also been shown to contribute to cell proliferation, cell adhesion, pH regulation of tumor cells and malignant cell invasion [12, 13], it is considered as a target for cancer diagnostics and treatment [14, 32]. Design and development of inhibitors for CAIX to hypoxic tumors remains a challenge [33, 34].

attention [29]. Thus, we report the binding features of coumarin derivatives with CAIX in the context of cancer (Figure 1).

Table 1: Chemical name of the coumarin derivatives

| COMPOUND | CHEMICAL NAME |
|----------|----------------|
| Compound 5 | 7-methoxy-2H-chromene-2-one |
| Compound 6 | 7-ethoxy-2H-chromene-2-one |
| Compound 7 | 7-propoxy-2H-chromene-2-one |
| Compound 11 | 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid |
| Compound 12 | 2-oxo-2H-chromene-3-carboxylic acid |
| Compound 13 | 6-methyl-2-oxo-2H-chromene-3-carboxylic acid |
| Compound 14 | 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid |
| Compound 15 | 6-(hydroxymethyl)-2-oxo-2H-chromene-3-carboxylic acid |
| Compound 16 | 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid |
| Compound 17 | 2-oxo-2H-thiophene-3-carboxylic acid |
| Compound 18 | methyl 6-(hydroxymethyl)-2-oxo-2H-chromene-3-carboxylate |
| Compound 19 | ethyl 6-(hydroxymethyl)-2-oxo-2H-chromene-3-carboxylate |
| Compound 20 | ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate |
| Compound 21 | 6-(hydroxymethyl)-2H-chromene-2-one |
| Compound 22 | 6-(aminomethyl)-2H-chromene-2-one |
| Compound 41 | N(3,4,5-trimethoxy-phenyl)-carbamoylmethyl |
| Compound 42 | N-(2,6-dimethylphenyl)-carbamoylmethyl |

Native ligand: N-propionyl-1,3,4-thiadiazol-5-yloxyamide

Figure 1: Graphical abstract for the study

The design and development of compounds as drug like compounds from natural products is classical in modern medicine [15-18]. It is of interest to design carbonic anhydrase IX (CAIX) inhibitors with improved features using molecular docking based virtual high throughput screening of ligands [19, 20]. Coumarin is known as a potent phythal compound from natural source blocking tumor growth. Coumarin (2H-chromen-2-one) and their derivatives are widely distributed in nature and exhibit a broad pharmacological activity [21]. Number of synthetic and natural coumarin derivatives have been reported to many studies such as antimicrobial [22, 23], analgesic- anti-inflammatory (24) and anticancer activity [25-28]. A report has demonstrated that coumarin substituted benzothiazole suppresses the protein tyrosine kinase activity and the use of coumarin in cancer therapy is gaining

Figure 2: Three-dimensional crystal structure of carbonic anhydrase IX (PDB ID: 3IAI)

Methodology:
Target
The protein molecule chosen for the docking studies is carbonic anhydrase-IX. The target structure data is downloaded from the Protein Data Bank (PDB: http://www.rcsb.org/pdb/home/home.do). The crystal structure of the protein taken for the docking studies (PDB code: 3IAI) with resolution of 2.2 Å is shown in Figure 2. Water molecules are removed from the structure and hydrogen atom was added for further process.
Bioinformation 2019, 15(10): 744-749

Ligand selection and preparation:
A total of 17 derivatives of coumarin were selected for molecular screening, based on comprehensive literature survey for natural compounds with anti-tumor activity. Ligand structures are drawn using the CHEMSKETCH software (Table 1). This is used for high throughput virtual screening of a new potential drug for CAIX. Minimization by geometric optimization using OPLS_2005 is carried out for ligands to have correct bond orders and bond angles.

Grid generation:
Residues of each active site in CAIX were scaled with a van der Waals’s radii of 1.0 Å having partial atomic charge less than 0.25 Å. The grid was generated around active sites using QSITEFINDER and SITEMAP enclosed by a box at the center of selected residues.

Docking studies:
CAIX docking with coumarin was completed using the GLIDE docking tool. Glide score contain a number of parameters such as vDW, Hydrogen bond (H bond), columbic (Coul), hydrophobic (Lipo), polar interactions in the binding site (site), metal binding term (metal) and penalty for buried polar group (Burry P) and freezing rotatable bonds (RotB).

ADME/T properties:
Absorption, Distribution, Metabolism, Excretion and Toxicity (ADME/T) properties of the docked molecules were predicted using QIKPROP tool in Schrodinger. This predicts the properties such as logBB, octanol/water partition, overall CNS activity and logIC50 values.

Results:
The crystal structure of CAIX (PDB ID: 3IAI), with a resolution of 2.20 Å (Figure 2) and coumarin derivatives shown in Table 1 were used for the docking studies. The structures of ligands were drawn using the CHEMSKETCH software. Energy minimization was done by using OPLS-AA force field. The protein structure and the ligands of coumarin derivatives are subjected to High Throughput Virtual Screening (HTVS) using yje GLIDE HTVS 5 module. The possible conformations of the best ligands and native ligand along with their docking score and Glide energy is given in Table 2. HTVS 5 selected compounds were subjected to Induced Fit Docking (IFD). IFD allows the receptor to alter its binding sites to mimic the shape and binding mode of the ligand. IFD were carried out between the target protein and screened ligands using GLIDE followed by PYMOL visualization. Table 3 and Figure 3 shows the possible conformations of best ligands comparing the native ligand along with their docking score and GLIDE energy. The ADME/T properties of these compounds were further analyzed using the QIKPROP tool of Schrodinger software. This is followed by PASS prediction on the basis of activity proportional to structure.

Discussion:
Carbonic anhydrase IX has a very high catalytic activity for the hydration of carbon dioxide to bicarbonate and protons. This is used as a marker of tumor hypoxia and as a prognostic factor for many human cancers. Coumarins constitute totally a new class of inhibitors of the zinc enzyme carbonic anhydrase, which bind at the entrance of the active site. The PDB structure (PDB ID: 3IAI) and

Table 2: High throughput virtual screening results of 17 Ligands (coumarin derivatives) against the Target Carbonic anhydrase (CA IX)

| Ligand | Docking Score | Glide Energy | Hydrogen Bond | Distance A |
|--------|---------------|--------------|---------------|------------|
| Compound 1 | -19.26 | -32.05 | H12-N2 | 2.89 |
| Compound 2 | -20.23 | -32.72 | H16-N4 | 3.14 |
| Compound 3 | -21.24 | -33.72 | H12-N2 | 3.21 |
| Compound 4 | -22.25 | -34.72 | H16-N4 | 3.28 |

Table 3: Induced fit docking results of 5 ligands with the target carbonic anhydrase

| Ligand | Docking Score | Glide Energy | Hydrogen Bond | Distance A |
|--------|---------------|--------------|---------------|------------|
| Compound 1 | -19.26 | -32.05 | H12-N2 | 2.89 |
| Compound 2 | -20.23 | -32.72 | H16-N4 | 3.14 |
| Compound 3 | -21.24 | -33.72 | H12-N2 | 3.21 |
| Compound 4 | -22.25 | -34.72 | H16-N4 | 3.28 |

ISSN 0973-2063 (online) 0973-8894 (print) Bioinformation 15(10): 744-749 (2019) ©Biomedical Informatics (2019)
the coumarin derivatives were used for docking analysis. The ligands did not have correct bond orders and bond angles. Hence, the missing hydrogen atoms and unfilled valence atoms were corrected using the OPLS_2005 force field. The active sites are predicted using Q-SITE FINDER and SITEMAP [30, 31] for further screening and docking analysis. GLIDE module from the Schrodinger package is used for docking analysis. All the ligands were minimized and subjected to High Throughput Virtual Screening (Table 2). Parameter such as G-Score, Glide Energy, H-bonds and Good Van-der-walls interactions were estimated. The more negative value of GLIDE score indicates that good binding affinity of ligand with receptor.

Five ligands with good score, energy and hydrogen bonding are selected for Induced Fit Docking studies from HTVS screening. Docking score and GLIDE energy of co-crystal ligand is (-7.54), (-43.82 kcal/mol) were calculated using IFD. Further, interactions with the residues (THR 199, PRO 201, HIS 119 and HIS 94) were observed. Ligand #41 has best score (-8.92) and energy (-61.58 kcal/mol) compared with other compounds. Hydrogen bonding with the residues (THR 200, THR 199) was seen. Ligand 42, Ligand 19 and ligand 15 also exhibit good interactions with the receptor. Ligand 42 has docking score (-8.77), GLIDE energy (-58.77 Kcal/mol) and hydrogen bonding with the residues (VAL 19, GLN 2, TRP 5). Ligand 19 has a docking score (-8.43), Glide energy (-45.12 Kcal/mol) and hydrogen bonding with the residues (GLN 92, THR 200, HIS 122, THR 199). Ligand 15 has a docking score (-7.86), Glide energy (-38.61 Kcal/mol) and interactions with the residues (THR 200, THR 199, HIS 94, HIS 122). Moreover, these compounds satisfy Lipinski’s rule of five and absorption, distribution, metabolism, excretion and toxicity (ADMET) properties for further consideration. Additionally, PASS prediction shows that ligand 41 have 43 possible biological activity. It shows activity and inhibitor values for oxido reductase Pa (0.817) and Pi (0.008); diuretic Pa (0.768) and Pi (0.003) anti glaucomic Pa (0.602) and Pi (0.004) and carbonic anhydrase Pa (0.324) and Pi (0.002). It is further shown that ligand 42 shows 25 possible biological activity data (data not shown) while the native ligand shows 107 possible biological activity data (data not shown) features.

Conclusion:
We show that N-(3,4,5-trimethoxy-phenylcarbamoylmethyl) designated as compound #41 have the highest binding energy (-61.58) with optimal interactions with the catalytic residues (THR 199, PRO 201, HIS 119, HIS 94) of CAIX for further consideration and evaluation using in vitro and in vivo models.

References
[1] Gong L et al. Oncogene 2003 22:4702. [PMID: 14576837]
[2] Choi YH et al. International Journal of Oncology 1998 13:391. [PMID: 9664138]
[3] Winum JY et al. Medicinal Research Reviews 2008 28:445. [PMID: 17880011]
[4] Kalinin S et al. Journal of Enzyme Inhibition and Medicinal Chemistry 2016 31:185. [PMID: 27784162]
[5] Karioti A et al. Molecules 2016 21:1649. [PMID: 27918439]
[6] Mahon BP et al. Molecules 2015 20:2323. [PMID: 25647573]
[7] Li JB et al. Future Oncology 2015 11:1531. [PMID: 30730778]
[8] Chiche J et al. Advances in Enzyme Regulation 2010 50:20. [PMID: 19895836]
[9] Wykoff CC et al. Cancer Research 2000 60:7075. [PMID: 11156414]
[10] Potter C & Harris AL, Cell Cycle 2004 3:164. [PMID: 14712082]
[11] Hon WC et al. Nature 2002 417:975. [PMID: 12050673]
[12] Ivan M et al. Science 2001 292:464. [PMID: 11292862]
[13] Maresca A et al. Journal of the American Chemical Society 2009 131:3057. [PMID: 19206230]
[14] Swietach P et al. The Journal of Biological Chemistry 2008 283:20473. [PMID: 18482982]
[15] Li JW et al. Science 2009 325: 161. [PMID: 19589993]
[16] Pratheeshkumar P et al. Anti-Cancer Agents in Medicinal Chemistry 2012 12: 1159. [PMID: 22583402]
[17] Unnati S et al. Chinese Journal of Natural Medicines 11:0016. [PMID: 15099842]
[18] Ozensoy O et al. Biochemistry 2004 69:216. [PMID: 16206834]
[19] Jorgensen WL & Duffy EM, Advanced Drug Delivery Reviews 2002 54:355. [PMID: 11922952]
[20] Jorgensen WL & Duffy EM, Bioorganic & Medicinal Chemistry Letters 2000 10:1155. [PMID: 10866370]
[21] Supuran CT et al. Medicinal Research Reviews 2003 23:146. [PMID: 12500287]
[22] Clark AM & Perrin DD, Biochemical Journal 1951 48:495. [PMID: 14838873]
[23] Kim G et al. Archives of Biochemistry and Biophysics 2000 377:334. [PMID: 15509976]
[24] Ghate M et al. European Journal of Medicinal Chemistry 2005 40:882. [PMID: 16140424]
[25] Kiese M, Naturwissenschaften 1941 29:116. [PMID: 20627072]
[26] Shanthi MP et al. International Journal of Pharmaceutical Sciences and Research 2016 7:5128. [PMID: 26085941]
[27] Shanthi MP et al. Indian Journal of Medical Research and Pharmaceutical Sciences 2016 3:157164. [PMID: 22583408]
[28] Andreucci E et al. Journal of Enzyme Inhibition and Medicinal Chemistry 2019 34:117. [PMID: 30362384]
[29] Vennila et al. Bioinformation 2014 10:263. [PMID: 24966532]
[30] Bupesh G et al. International Journal of Drug Development and Research 2014 6:205. [PMID: 29091800]
[31] Baba M et al. Biological and Pharmaceutical Bulletin 2002 25:244. [PMID: 11853175]
[32] Koyuncu et al. Journal of Enzyme Inhibition and Medicinal Chemistry 2019 34:703.
[33] Meijer TW et al. PLoS One 2014 9: e108068. [PMID: 25225880].
[34] Muller V et al. Breast Cancer Research. 2011 13:R71.
